Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 269

1.

Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease.

Zambon A, Zhao XQ, Brown BG, Brunzell JD.

Am J Cardiol. 2014 May 1;113(9):1494-8. doi: 10.1016/j.amjcard.2014.01.426. Epub 2014 Feb 11.

PMID:
24641964
[PubMed - indexed for MEDLINE]
2.

Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.

White HD, Simes J, Stewart RA, Blankenberg S, Barnes EH, Marschner IC, Thompson P, West M, Zeller T, Colquhoun DM, Nestel P, Keech AC, Sullivan DR, Hunt D, Tonkin A; LIPID Study Investigators.

J Am Heart Assoc. 2013 Oct 23;2(5):e000360. doi: 10.1161/JAHA.113.000360.

PMID:
24152981
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis.

Martin SS, Blaha MJ, Blankstein R, Agatston A, Rivera JJ, Virani SS, Ouyang P, Jones SR, Blumenthal RS, Budoff MJ, Nasir K.

Circulation. 2014 Jan 7;129(1):77-86. doi: 10.1161/CIRCULATIONAHA.113.003625. Epub 2013 Oct 20.

PMID:
24141324
[PubMed - indexed for MEDLINE]
4.

Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial.

Kim SH, Kim MK, Seo HS, Hyun MS, Han KR, Cho SW, Kim YK, Hoon Park S.

Clin Ther. 2013 Sep;35(9):1350-60.e1. doi: 10.1016/j.clinthera.2013.06.020. Epub 2013 Aug 30.

PMID:
23998970
[PubMed - indexed for MEDLINE]
5.

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ.

Circulation. 2013 Oct 1;128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21.

PMID:
23965489
[PubMed - indexed for MEDLINE]
6.

Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.

Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, Sattar N; ASCOT Investigators.

J Am Coll Cardiol. 2013 Aug 20;62(8):717-29. doi: 10.1016/j.jacc.2013.02.098.

PMID:
23948514
[PubMed - indexed for MEDLINE]
Free Article
7.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
[PubMed - indexed for MEDLINE]
8.

A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.

Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, Lele A, Stolzenbach JC.

Clin Ther. 2013 Aug;35(8):1186-98. doi: 10.1016/j.clinthera.2013.06.013. Epub 2013 Jul 26. Erratum in: Clin Ther. 2013 Nov;35(11):1862.

PMID:
23891363
[PubMed - indexed for MEDLINE]
Free Article
9.

Pitavastatin in cardiometabolic disease: therapeutic profile.

Masana L.

Cardiovasc Diabetol. 2013;12 Suppl 1:S2. doi: 10.1186/1475-2840-12-S1-S2. Epub 2013 May 30. Review.

PMID:
23819752
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Statins in cardiometabolic disease: what makes pitavastatin different?

Ginsberg H.

Cardiovasc Diabetol. 2013;12 Suppl 1:S1. doi: 10.1186/1475-2840-12-S1-S1. Epub 2013 May 30. Review.

PMID:
23819727
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Low-density lipoprotein cholesterol: how low can we go?

Sherbet DP, Garg P, Brilakis ES, Banerjee S.

Am J Cardiovasc Drugs. 2013 Aug;13(4):225-32. doi: 10.1007/s40256-013-0013-8. Review.

PMID:
23609530
[PubMed - indexed for MEDLINE]
12.

Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study.

Sondermeijer BM, Boekholdt SM, Rana JS, Kastelein JJ, Wareham NJ, Khaw KT.

Eur Heart J. 2013 May;34(18):1350-7. doi: 10.1093/eurheartj/eht047. Epub 2013 Feb 28.

PMID:
23449857
[PubMed - indexed for MEDLINE]
Free Article
13.

Statins for the primary prevention of cardiovascular disease.

Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S.

Cochrane Database Syst Rev. 2013 Jan 31;1:CD004816. doi: 10.1002/14651858.CD004816.pub5. Review.

PMID:
23440795
[PubMed - indexed for MEDLINE]
14.

Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?

Ridker PM.

Curr Atheroscler Rep. 2013 Jan;15(1):295. doi: 10.1007/s11883-012-0295-3. Review.

PMID:
23225175
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

[Deficits in lipid lowering therapy and achieving target lipid concentrations in patients with high risk of a cardiovascular event].

Petrus J, Málek F, Dvořák J, Mates M, Kmoníček P, Skalníková V, Neužil P.

Vnitr Lek. 2012 Jun;58(6):430-3. Czech.

PMID:
22913234
[PubMed - indexed for MEDLINE]
16.

Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study.

Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, Kostara C, Gartzonika C, Bairaktari ET, Milionis HJ.

J Cardiovasc Pharmacol Ther. 2013 Jan;18(1):5-12. doi: 10.1177/1074248412445506. Epub 2012 May 9.

PMID:
22573476
[PubMed - indexed for MEDLINE]
17.

Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.

Shinozaki T, Matsuyama Y, Iimuro S, Umegaki H, Sakurai T, Araki A, Ohashi Y, Ito H; Japanese Elderly Diabetes Intervention Trial Research Group.

Geriatr Gerontol Int. 2012 Apr;12 Suppl 1:88-102. doi: 10.1111/j.1447-0594.2011.00816.x.

PMID:
22435944
[PubMed - indexed for MEDLINE]
18.

The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial.

Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM.

CMAJ. 2012 Apr 17;184(7):E367-72. doi: 10.1503/cmaj.111017. Epub 2012 Mar 19.

PMID:
22431901
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

South African dyslipidaemia guideline consensus statement.

Klug E; South African Heart Association (S A Heart); Lipid and Atherosclerosis Society of Southern Africa (LASSA).

S Afr Med J. 2012 Feb 23;102(3 Pt 2):178-87.

PMID:
22380916
[PubMed - indexed for MEDLINE]
20.

Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 40,600 participants in the rosuvastatin clinical development program.

Stein EA, Vidt DG, Shepherd J, Cain VA, Anzalone D, Cressman MD.

Atherosclerosis. 2012 Apr;221(2):471-7. doi: 10.1016/j.atherosclerosis.2011.12.011. Epub 2012 Jan 3.

PMID:
22304793
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk